利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.021 秒)

    Sustained release compositions containing alfuzosin
    1.
    发明申请
    Sustained release compositions containing alfuzosin 审中-公开
    含有阿夫唑嗪的缓释组合物

    公开(公告)号：US20060147530A1

    公开(公告)日：2006-07-06

    申请号：US10532296

    申请日：2003-10-22

    申请人： Narayanan Viswanathan ,  Sankar Ramakrishnan ,  Rajeev Singh Raghuvanshi ,  Ashok Rampal

    发明人： Narayanan Viswanathan ,  Sankar Ramakrishnan ,  Rajeev Singh Raghuvanshi ,  Ashok Rampal

    IPC分类号： A61K9/26

    CPC分类号： A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2866 ,  A61K31/195 ,  A61K31/517

    摘要： The present invention relates to pharmaceutical compositions of alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof, that release the active ingredient over an extended period of time. The pharmaceutical composition can be a sustained release oral dosage form that includes a single functional layer and, optionally, one or more nonfunctional layers adjacent to the single functional layer. The single functional layer includes alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof and one or more release retarding ingredients.

    摘要翻译： 本发明涉及在长时间内释放活性成分的阿夫唑嗪或其药学上可接受的盐，溶剂合物，对映异构体或其混合物的药物组合物。 药物组合物可以是持续释放口服剂型，其包括单个功能层和任选的一个或多个与单个功能层相邻的非功能层。 单功能层包括阿夫唑嗪或其药学上可接受的盐，溶剂合物，对映异构体或其混合物和一种或多种释放阻滞成分。

    MODIFIED-RELEASE FORMULATIONS OF AZABICYCLO DERIVATIVES
    4.
    发明申请
    MODIFIED-RELEASE FORMULATIONS OF AZABICYCLO DERIVATIVES 审中-公开
    改性释放丙氨酸衍生物的制剂

    公开(公告)号：US20100152269A1

    公开(公告)日：2010-06-17

    申请号：US12519479

    申请日：2007-12-21

    申请人： Anant Ramesh Ketkar ,  Pratik Kumar ,  Ashok Rampal

    发明人： Anant Ramesh Ketkar ,  Pratik Kumar ,  Ashok Rampal

    IPC分类号： A61K31/403 ,  A61P11/00 ,  A61P1/00 ,  A61P13/00

    CPC分类号： A61K31/403 ,  A61K9/0004 ,  A61K9/2027 ,  A61K9/2054

    摘要： The present invention discloses modified-release oral dosage forms of an azabicyclo derivative or its pharmaceutically acceptable salts, solvates, esters, enantiomers, diastereomers, N-oxides and polymorphs; and processes for the preparation thereof. The modified release formulation comprises an azabicyclo derivative, at least one rate-controlling polymer and at least one pharmaceutically acceptable excipient which provides therapeutically effective plasma levels of the active ingredient for a period of up to 24 hours.

    摘要翻译： 本发明公开了氮杂双环衍生物或其药学上可接受的盐，溶剂合物，酯，对映异构体，非对映异构体，N-氧化物和多晶型物的改良释放口服剂型; 及其制备方法。 改性释放制剂包含氮杂二环衍生物，至少一种速率控制聚合物和至少一种药学上可接受的赋形剂，其提供活性成分的治疗有效血浆水平达24小时。

    MULTILAYERED MODIFIED RELEASE FORMULATION COMPRISING AMOXICILLIN AND CLAVULANATE
    5.
    发明申请
    MULTILAYERED MODIFIED RELEASE FORMULATION COMPRISING AMOXICILLIN AND CLAVULANATE 审中-公开
    包含AMOXICILIN和CLAVULANATE的多层改性释放配方

    公开(公告)号：US20110020408A1

    公开(公告)日：2011-01-27

    申请号：US12600590

    申请日：2008-05-16

    申请人： Kalaiselvan Ramaraju ,  Rajan Kumar Verma ,  Ashok Rampal

    发明人： Kalaiselvan Ramaraju ,  Rajan Kumar Verma ,  Ashok Rampal

    IPC分类号： A61K9/00 ,  A61K31/43 ,  A61P31/00

    CPC分类号： A61K9/209 ,  A61K31/424 ,  A61K31/43 ,  A61K2300/00

    摘要： The present invention relates to multilayered modified release formulation comprising amoxicillin and clavulanate, process of preparation thereof and method of treating bacterial infection using these formulations. The multilayered modified release formulation comprises: an immediate release layer comprising amoxicillin and clavulanate; and a slow release layer comprising amoxicillin and one or more release retarding agents; and one or more non-release controlling inert barrier layers placed in between the immediate release layer and the slow release layer and comprising one or more pharmaceutically acceptable excipients.

    摘要翻译： 本发明涉及包含阿莫西林和克拉维酸的多层改性释放制剂，其制备方法和使用这些制剂治疗细菌感染的方法。 多层改性释放制剂包括：包含阿莫西林和克拉维酸的立即释放层; 以及包含阿莫西林和一种或多种释放阻滞剂的缓释层; 以及一个或多个不释放控制的惰性阻挡层，其放置在速释层和缓释层之间并且包含一种或多种药学上可接受的赋形剂。

    Hydrodynamically balancing oral drug delivery system with biphasic release
    7.
    发明申请
    Hydrodynamically balancing oral drug delivery system with biphasic release 审中-公开
    流体动力平衡口服药物输送系统与双相释放

    公开(公告)号：US20060099245A1

    公开(公告)日：2006-05-11

    申请号：US10514674

    申请日：2002-05-21

    申请人： Manoj Kumar ,  Naresh Talwar ,  Rajeev Raghuvanshi ,  Ashok Rampal

    发明人： Manoj Kumar ,  Naresh Talwar ,  Rajeev Raghuvanshi ,  Ashok Rampal

    IPC分类号： A61K9/48 ,  A61K9/64 ,  A61K9/22 ,  A61K31/403

    CPC分类号： A61K9/0065 ,  A61K9/2866 ,  A61K9/4891

    摘要： The present invention relates to an oral drug delivery system with biphasic release characteristics comprising a porous matrix comprising at least one drug substance, sugar(s), a release retarding polymer, gas generating components and optionally, pharma-ceuti-cally acceptable auxiliary components wherein the pharmaceutical composition further comprises a coating of said drug substance. The pharmaceutical composi-tion, either in the form of pellets (multiparticulate or single unit dosage form), beads, granules, capsules or tablets, is retained in the stomach while selectively delivering the drug(s) at gastrointestinal levels and upper parts of the small intestine over an extended period of time. The release of the drug from the said pharmaceutical composition is characterized by a biphasic release profile of the drug substance, which exhibits both immediate and controlled release characteristics.

    摘要翻译： 本发明涉及具有双相释放特征的口服药物递送系统，其包含多孔基质，其包含至少一种药物物质，糖，缓释聚合物，气体产生组分和任选的药物可接受的辅助成分，其中 药物组合物还包含所述药物的涂层。 以颗粒形式（多颗粒或单一单位剂型），珠粒，颗粒，胶囊或片剂的药物组合物保留在胃中，同时选择性地将药物在胃肠水平和 小肠在较长时间内。 药物从所述药物组合物的释放的特征在于药物物质的双相释放曲线，其表现出立即和控制释放特征。

    Bupropion hydrochloride solid dosage forms
    8.
    发明申请
    Bupropion hydrochloride solid dosage forms 审中-公开
    盐酸安非他酮固体剂型

    公开(公告)号：US20060020040A1

    公开(公告)日：2006-01-26

    申请号：US10534910

    申请日：2003-11-17

    申请人： Manish Chawla ,  Rajeev Raghuvanshi ,  Ashok Rampal

    发明人： Manish Chawla ,  Rajeev Raghuvanshi ,  Ashok Rampal

    IPC分类号： A61K31/138

    CPC分类号： A61K31/135 ,  A61K9/2013 ,  A61K9/2054

    摘要： The present invention relates to solid dosage forms that contain bupropion hydrochloride and glucono delta lactone or its corresponding open chain hydroxy acid derivative. The bupropion hydrochloride retains at least 80% of the bupropion hydrochloride potency after storage for three months at 40° C. and 75% relative humidity. The solid dosage form may be in the form of a tablet, a capsule, or a granulate with or without an immediate release profile, a modified release profile, or an extended release profile.

    摘要翻译： 本发明涉及含有安非他酮盐酸盐和葡萄糖酸-δ内酯或其相应的开链羟基酸衍生物的固体剂型。 盐酸安非他酮在40℃和75％相对湿度下保存3个月后，保持盐酸安非他酮的至少80％的效力。 固体剂型可以是片剂，胶囊或具有或不具有立即释放特征，改变释放特征或延长释放特征的颗粒形式。

    EXTENDED RELEASE MATRIX FORMULATIONS OF MORPHINE
    10.
    发明申请
    EXTENDED RELEASE MATRIX FORMULATIONS OF MORPHINE 审中-公开
    扩展释放矩阵MORPHINE的配方

    公开(公告)号：US20080220064A1

    公开(公告)日：2008-09-11

    申请号：US11951885

    申请日：2007-12-06

    申请人： Ketkar Anant RAMESH ,  Pratik Kumar ,  Ashok Rampal

    发明人： Ketkar Anant RAMESH ,  Pratik Kumar ,  Ashok Rampal

    IPC分类号： A61K9/00 ,  A61K31/485

    CPC分类号： A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/485

    摘要： The present invention provides extended-release matrix formulations comprising a therapeutically effective amount of morphine or salt thereof, one or more hydrophilic controlled release polymers and one or more pharmaceutically acceptable excipients. The formulations provide extended release of morphine or salt thereof over a specified period of time after oral administration in humans or animals.

    摘要翻译： 本发明提供了包含治疗有效量的吗啡或其盐，一种或多种亲水控释聚合物和一种或多种药学上可接受的赋形剂的延长释放基质制剂。 在人或动物口服给药后，该制剂在指定的时间内提供吗啡或其盐的延长释放。